Anurag Duggal, MD
Infectious Disease · Cuyahoga Falls, OHNPI 1770762262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Merck at 25.0% of the total. 2025 is the largest year on record at $392, 9.5 times the $41 reported in 2019.
Across 21 payments — averaging $36.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$194
- Ferring Pharmaceuticals Inc.$125
- Abbott$104
- Insmed, Inc.$99
- La Jolla Pharmaceutical Company$96
- Cumberland Pharmaceuticals, Inc.$45
- plus $111 from 4 others
What the payments were for
- Food & beverage$76399%
- Education$111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $194 |
| Ferring Pharmaceuticals Inc. | 1 | $125 |
| Abbott | 1 | $104 |
| Insmed, Inc. | 6 | $99 |
| La Jolla Pharmaceutical Company | 1 | $96 |
| Cumberland Pharmaceuticals, Inc. | 2 | $45 |
| Viiv Healthcare Company | 1 | $41 |
| Shionogi Inc | 2 | $32 |
| Theratechnologies Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$774 in reported general payments places this provider in the 65th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 70 | $25,178 |
| ErtapenemErtapenem Sodium | 48 | $15,438 |
| Nafcillin Sodium | 13 | $11,663 |
| Meropenem | 22 | $5,449 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 32 | $4,647 |
| CeftriaxoneCeftriaxone Sodium | 84 | $4,150 |
| Cefepime Hcl | 12 | $1,472 |
| Doxycycline Hyclate | 20 | $373 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Cuyahoga Falls
- Steven BurdetteDayton$322K
- Nathaniel RatnasamyFindlay$255K
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Nicholas CongerWright Patterson Afb$76K
- Alan TaegeCleveland$76K
- Carlos MalvestuttoColumbus$70K
- Thomas FileAkron$68K
- Nelson NicolasoraToledo$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.